@article{Khan2019186,
title = {Crocodiles and alligators: Physicians’ answer to cancer?},
author = {N A Khan and M Soopramanien and R Siddiqui},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069313377&doi=10.3747%2fco.26.4855&partnerID=40&md5=6a266208d5fe14a1c888bb1db397d744},
doi = {10.3747/co.26.4855},
issn = {11980052},
year = {2019},
date = {2019-01-01},
journal = {Current Oncology},
volume = {26},
number = {3},
pages = {186},
publisher = {Multimed Inc.},
note = {cited By 1},
keywords = {Allergic Disease, Alligators and Crocodiles, Animal Product, Animals, Antineoplastic Activity, Antineoplastic Agent, Article, Atopic Dermatitis, Autism, Cancer Growth, Cancer Therapy, Carcinogen, Contaminated Organism, Crocodilian, End Cretaceous Mass Extinction, Environmental Factor, Environmental Stress, Gastrointestinal Microbiome, Health Behaviour, Heavy Metal, Human, Immune System, Inflammatory Bowel Disease, Intestine Flora, Longevity, Metabolic Disorder, Microbiology, Neoplasm, Neoplasms, Nerve Cell Differentiation, Physician, Schizophrenia, Survival Analysis, Terminal Disease},
pubstate = {published},
tppubtype = {article}
}

@article{Mohamad2019343,
title = {The α5-Containing GABA A Receptors—a Brief Summary},
author = {F H Mohamad and A T C Has},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059596842&doi=10.1007%2fs12031-018-1246-4&partnerID=40&md5=7b2ba0dc86c6c3f890f226cad8195ee5},
doi = {10.1007/s12031-018-1246-4},
issn = {08958696},
year = {2019},
date = {2019-01-01},
journal = {Journal of Molecular Neuroscience},
volume = {67},
number = {2},
pages = {343-351},
publisher = {Springer New York LLC},
abstract = {GABA A receptors are the major inhibitory neurotransmitter receptor in the human brain. The receptors are assembled from combination of protein subunits in pentameric complex which may consist of α1–6, β1–3, γ1–3, ρ1–3, δ, ε, θ, or π subunits. There are a theoretical > 150,000 possible assemblies and arrangements of GABA A subunits, although only a few combinations have been found in human with the most dominant consists of 2α1, 2β2, and 1γ2 in a counterclockwise arrangement as seen from the synaptic cleft. The receptors also possess binding sites for various unrelated substances including benzodiazepines, barbiturates, and anesthetics. The α5-containing GABA A Rs only make up ≤ 5% of the entire receptor population, but up to 25% of the receptor subtype is located in the crucial learning and memory-associated area of the brain—the hippocampus, which has ignited myriads of hypotheses and theories in regard to its role. As well as exhibiting synaptic phasic inhibition, the α5-containing receptors are also extrasynaptic and mediate tonic inhibition with continuously occurring smaller amplitude. Studies on negative-allosteric modulators for reducing this tonic inhibition have been shown to enhance learning and memory in neurological disorders such as schizophrenia, Down syndrome, and autism with a possible alternative benzodiazepine binding site. Therefore, a few α5 subunit-specific compounds have been developed to address these pharmacological needs. With its small population, the α5-containing receptors could be the key and also the answer for many untreated cognitive dysfunctions and disorders. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.},
note = {cited By 1},
keywords = {4 Aminobutyric Acid, 4 Aminobutyric Acid A Receptor, Alpha5 Containing 4 Aminobutyric Acid A Receptor, Animals, Autism, Brain, Cognitive Defect, Cognitive Dysfunction, Drug Effect, GABA Agents, GABA-A, GABAergic Receptor Affecting Agent, Genetics, Human, Metabolism, Nonhuman, Protein Subunit, Protein Subunits, Receptors, Review, Schizophrenia, Unclassified Drug},
pubstate = {published},
tppubtype = {article}
}

@article{EiThu2018865,
title = {New insight in improving therapeutic efficacy of antipsychotic agents: An overview of improved in vitro and in vivo performance, efficacy upgradation and future prospects},
author = {H Ei Thu and Z Hussain and A N Shuid},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048981535&doi=10.2174%2f1389450117666161125174625&partnerID=40&md5=d32e5bc9766ff9d68dd79f082b9ca4bc},
doi = {10.2174/1389450117666161125174625},
issn = {13894501},
year = {2018},
date = {2018-01-01},
journal = {Current Drug Targets},
volume = {19},
number = {8},
pages = {865-876},
publisher = {Bentham Science Publishers B.V.},
abstract = {Psychotic disorders are recognized as severe mental disorders that rigorously affect pa-tient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents. © 2018 Bentham Science Publishers.},
note = {cited By 2},
keywords = {Amisulpride, Amitriptyline, Animals, Antipsychotic Agents, Anxiety, Aripiprazole, Autism, Bioavailability, Biological Availability, Bipolar Disorder, Buspirone, Chemistry, Clonazepam, Clozapine, Depression, Diazepam, Drug Delivery System, Drug Delivery Systems, Duloxetine, Half Life Time, Half-Life, Health Care, Human, Iloperidone, In Vitro Study, In Vivo Study, Mental Disease, Mental Disorders, Midazolam, Nanotechnology, Neuroleptic Agent, Olanzapine, Pathophysiology, Permeability, Physical Chemistry, Psychosis, Review, Risperidone, Schizophrenia, Solubility, Sulpiride, Treatment Outcome, Venlafaxine, Ziprasidone},
pubstate = {published},
tppubtype = {article}
}

@article{Paudel2018145,
title = {Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy},
author = {Y N Paudel and M F Shaikh and S Shah and Y Kumari and I Othman},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053082063&doi=10.1016%2fj.ejphar.2018.08.020&partnerID=40&md5=27ff0199bae72f156425637a7ad02228},
doi = {10.1016/j.ejphar.2018.08.020},
issn = {00142999},
year = {2018},
date = {2018-01-01},
journal = {European Journal of Pharmacology},
volume = {837},
pages = {145-155},
publisher = {Elsevier B.V.},
abstract = {Epilepsy is a devastating condition affecting around 70 million people worldwide. Moreover, the quality of life of people with epilepsy (PWE) is worsened by a series of comorbidities. The neurobehavioral comorbidities discussed herein share a reciprocal and complex relationship with epilepsy, which ultimately complicates the treatment process in PWE. Understanding the mechanistic pathway by which these comorbidities are associated with epilepsy might be instrumental in developing therapeutic interventions. Inflammatory cytokine signaling in the brain regulates important brain functions including neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, dopaminergic transmission, the kynurenine pathway, and affects neurogenesis as well as the neural circuitry of moods. In this review, we hypothesize that the complex relationship between epilepsy and its related comorbidities (cognitive impairment, depression, anxiety, autism, and schizophrenia) can be unraveled through the inflammatory mechanism that plays a prominent role in all these individual conditions. An ample amount of evidence is available reporting the role of inflammation in epilepsy and all individual comorbid condition but their complex relationship with epilepsy has not yet been explored through the prospective of inflammatory pathway. Our review suggests that epilepsy and its neurobehavioral comorbidities are associated with elevated levels of several key inflammatory markers. This review also sheds light on the mechanistic association between epilepsy and its neurobehavioral comorbidities. Moreover, we analyzed several anti-inflammatory therapies available for epilepsy and its neurobehavioral comorbidities. We suggest, these anti-inflammatory therapies might be a possible intervention and could be a promising strategy for preventing epileptogenesis and its related neurobehavioral comorbidities. © 2018 Elsevier B.V.},
note = {cited By 14},
keywords = {3 Dioxygenase, Acetylsalicylic Acid, Adalimumab, Anakinra, Animals, Anti-Inflammatory Agents, Anxiety, Autacoid, Autism, Autism Spectrum Disorders, Behaviour Disorder, Belnacasan, Celecoxib, Cognition, Comorbidity, Complication, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitor, Cytokine, Cytokines, Depression, Dexmedetomidine, Disease Association, Dopaminergic Transmission, Electroencephalogram, Electroencephalography, Epilepsy, Epileptogenesis, Esculetin, High Mobility Group B1 Protein, Human, Ibuprofen, Icariin, IImmunoglobulin Enhancer Binding Protein, Immunology, Indoleamine 2, Inflammation, Inflammation Mediators, Infliximab, Interleukin 1beta, Interleukin 6, Minocycline, Nerve Cell Plasticity, Nervous System Development, Nervous System Inflammation, Neuroendocrine Regulation, Neurotransmitter Release, Nonhuman, Palmidrol, Paracetamol, Physiology, Priority Journal, Prostaglandin E2, Psychology, Review, SC 51089, Schizophrenia, Toll-Like Receptor 4, Transforming Growth Factor Beta, Tryptophan Hydroxylase, Tumor Necrosis Factor, Unclassified Drug},
pubstate = {published},
tppubtype = {article}
}

@article{Charara2017,
title = {The burden of mental disorders in the eastern mediterranean region, 1990-2013},
author = {R Charara and M Forouzanfar and M Naghavi and M Moradi-Lakeh and A Afshin and T Vos and F Daoud and H Wang and C E Bcheraoui and I Khalil and R R Hamadeh and A Khosravi and V Rahimi-Movaghar and Y Khader and N Al-Hamad and C M Obermeyer and A Rafay and R Asghar and S M Rana and A Shaheen and N M E Abu-Rmeileh and A Husseini and L J Abu-Raddad and T Khoja and Z A A Rayess and F S AlBuhairan and M Hsairi and M A Alomari and R Ali and G Roshandel and A S Terkawi and S Hamidi and A H Refaat and R Westerman and A A Kiadaliri and A S Akanda and S D Ali and U Bacha and A Badawi and S Bazargan-Hejazi and I A D Faghmous and S -M Fereshtehnejad and F Fischer and J B Jonas and B K Defo and A Mehari and S B Omer and F Pourmalek and O A Uthman and A A Mokdad and F T Maalouf and F Abd-Allah and N Akseer and D Arya and R Borschmann and A Brazinova and T S Brugha and F Catala-Lopez and L Degenhardt and A Ferrari and J M Haro and M Horino and J C Hornberger and H Huang and C Kieling and D Kim and Y Kim and A K Knudsen and P B Mitchell and G Patton and R Sagar and M Satpathy and K Savuon and S Seedat and I Shiue and J C Skogen and D J Stein and K M Tabb and H A Whiteford and P Yip and N Yonemoto and C J L Murray and A H Mokdad},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009892168&doi=10.1371%2fjournal.pone.0169575&partnerID=40&md5=471830ec1239e37c6fc4681bed5698f6},
doi = {10.1371/journal.pone.0169575},
issn = {19326203},
year = {2017},
date = {2017-01-01},
journal = {PLoS ONE},
volume = {12},
number = {1},
publisher = {Public Library of Science},
abstract = {The Eastern Mediterranean Region (EMR) is witnessing an increase in chronic disorders, including mental illness. With ongoing unrest, this is expected to rise. This is the first study to quantify the burden of mental disorders in the EMR. We used data from the Global Burden of Disease study (GBD) 2013. DALYs (disability-adjusted life years) allow assessment of both premature mortality (years of life lost-YLLs) and nonfatal outcomes (years lived with disability-YLDs). DALYs are computed by adding YLLs and YLDs for each age-sex-country group. In 2013, mental disorders contributed to 5.6% of the total disease burden in the EMR (1894 DALYS/100,000 population): 2519 DALYS/100,000 (2590/100,000 males, 2426/100,000 females) in high-income countries, 1884 DALYS/100,000 (1618/100,000 males, 2157/100,000 females) in middle-income countries, 1607 DALYS/100,000 (1500/100,000 males, 1717/100,000 females) in low-income countries. Females had a greater proportion of burden due to mental disorders than did males of equivalent ages, except for those under 15 years of age. The highest proportion of DALYs occurred in the 25-49 age group, with a peak in the 35-39 years age group (5344 DALYs/100,000). The burden of mental disorders Burden of Mental Disorders in EMR PLOS ONE in EMR increased from 1726 DALYs/100,000 in 1990 to 1912 DALYs/100,000 in 2013 (10.8% increase). Within the mental disorders group in EMR, depressive disorders accounted for most DALYs, followed by anxiety disorders. Among EMR countries, Palestine had the largest burden of mental disorders. Nearly all EMR countries had a higher mental disorder burden compared to the global level. Our findings call for EMR ministries of health to increase provision of mental health services and to address the stigma of mental illness. Moreover, our results showing the accelerating burden of mental health are alarming as the region is seeing an increased level of instability. Indeed, mental health problems, if not properly addressed, will lead to an increased burden of diseases in the region. © 2017 Charara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.},
note = {cited By 30},
keywords = {80 and Over, Adolescent, Adult, Age, Age Factors, Aged, Anxiety Disorder, Article, Attention Deficit Disorder, Autism, Bipolar Disorder, Children, Conduct Disorder, Depression, Elderly People, Female, Global Health, Groups by Age, Health Status, Highest Income Group, Human, Infant, Intellectual Impairment, Kuwait, Life Expectancy, Major Clinical Study, Male, Mediterranean Region, Mental Disease, Mental Disorders, Mental Health, Mental Health Service, Middle Aged, Middle Income Group, Mortality, Newborn, Palestine, Premature Mortality, Preschool, Preschool Child, Prevalence, Qatar, Quality Adjusted Life Year, Schizophrenia, Sex Difference, Sex Factors, Southern Europe, Time Factor, Time Factors, United Arab Emirates, Young Adult},
pubstate = {published},
tppubtype = {article}
}

@article{Cheah2012451,
title = {Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3ζ deficiency},
author = {P -S Cheah and H S Ramshaw and P Q Thomas and K Toyo-Oka and X Xu and S Martin and P Coyle and M A Guthridge and F Stomski and M Van Den Buuse and A Wynshaw-Boris and A F Lopez and Q P Schwarz},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859007028&doi=10.1038%2fmp.2011.158&partnerID=40&md5=7f507fef31a192a10b3cde7bf69b5442},
doi = {10.1038/mp.2011.158},
issn = {13594184},
year = {2012},
date = {2012-01-01},
journal = {Molecular Psychiatry},
volume = {17},
number = {4},
pages = {451-466},
abstract = {Complex neuropsychiatric disorders are believed to arise from multiple synergistic deficiencies within connected biological networks controlling neuronal migration, axonal pathfinding and synapse formation. Here, we show that deletion of 14-3-3ζ causes neurodevelopmental anomalies similar to those seen in neuropsychiatric disorders such as schizophrenia, autism spectrum disorder and bipolar disorder. 14-3-3ζ-Deficient mice displayed striking behavioural and cognitive deficiencies including a reduced capacity to learn and remember, hyperactivity and disrupted sensorimotor gating. These deficits are accompanied by subtle developmental abnormalities of the hippocampus that are underpinned by aberrant neuronal migration. Significantly, 14-3-3ζ- deficient mice exhibited abnormal mossy fibre navigation and glutamatergic synapse formation. The molecular basis of these defects involves the schizophrenia risk factor, DISC1, which interacts isoform specifically with 14-3-3ζ. Our data provide the first evidence of a direct role for 14-3-3ζ deficiency in the aetiology of neurodevelopmental disorders and identifies 14-3-3ζ as a central risk factor in the schizophrenia protein interaction network. © 2012 Macmillan Publishers Limited All rights reserved.},
note = {cited By 58},
keywords = {14-3-3 Proteins, Animal Experiment, Animal Model, Animal Tissue, Animals, Article, Autism, Behaviour Disorder, Bipolar Disorder, Brain, Cell Movement, Cells, Cognitive Defect, Controlled Study, Cultured, Disease Models, Disrupted in Schizophrenia 1 Protein, Embryo, Female, Gene, Gene Deletion, Genetic Predisposition to Disease, Glutamic Acid, Hippocampal Mossy Fiber, Hippocampus, Human, Hyperactivity, Inbred C57BL, Isoprotein, Knockout, Learning, Male, Maze Learning, Memory, Mice, Motor Activity, Mouse, Neurogenesis, Neuronal Migration Disorder, Neurons, Neuropsychiatry, Nonhuman, Priority Journal, Protein 14-3-3, Protein 14-3-3 Zeta, Protein Deficiency, Protein Interaction, Recognition, Risk Factor, Schizophrenia, Sensory Gating, Synapse, Unclassified Drug},
pubstate = {published},
tppubtype = {article}
}

@article{Patel2010169,
title = {Reducing the treatment gap for mental disorders: A WPA survey},
author = {V Patel and M Maj and A J Flisher and M J De Silva and M Koschorke and M Prince and R Tempier and M B Riba and M Sanchez and F D Campodonico and L Risco and L Gask and H Wahlberg and M Roca and D Lecic-Tosevski and A Soghoyan and D Moussaoui and C Baddoura and J Adeyemi and S Rataemane and S A Jalili and E Mohandas and N Shinfuku and J Freidin and J C Stagnaro and I J Puig and K Kirkby and M Musalek and N Ismayilov and G Rabbani and S Harvey and B Sabbe and N Noya-Tapia and M Burgic-Radmanovic and L A Hetem and F Vasconcellos and J Maass and C Miranda and N Papaneophytou and J Raboch and A Fink-Jensen and A Okasha and J Korkeila and J D Guelfi and F Schneider and S Ohene and G Christodoulou and C R Soldatos and S K E Q Barrera and M Mendoza and R A Kallivayalil and S S Gudarzi and M R Lafta and M Bassi and M Clerici and R Gibson and T Kojima and S Nurmagambetova and S -C Cho and T Kadyrova and N Mikati and S Bajraktarov and T H Yen and B Ayushjav and L I Stevovic and J S S Molina and O Gureje and J O Johannessen and H R Chaudhry and B Al-Ashhab and A Araszkiewicz and D Prelipceanu and V Krasnov and A Bogdanov and M Jasovic-Gasic and L Vavrusova and P Pregelj and A F Liria and A Abdelrahman and P Udomratn and H Ulas and P Gokaip and F N Kigozi and G Richardson},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79851492757&doi=10.1002%2fj.2051-5545.2010.tb00305.x&partnerID=40&md5=ebf47e1e84f22271aea10a73c93e9892},
doi = {10.1002/j.2051-5545.2010.tb00305.x},
issn = {17238617},
year = {2010},
date = {2010-01-01},
journal = {World Psychiatry},
volume = {9},
number = {3},
pages = {169-176},
publisher = {Blackwell Publishing Ltd},
abstract = {The treatment gap for people with mental disorders exceeds 50% in all countries of the world, approaching astonishingly high rates of 90% in the least resourced countries. We report the findings of the first systematic survey of leaders of psychiatry in nearly 60 countries on the strategies for reducing the treatment gap. We sought to elicit the views of these representatives on the roles of different human resources and health care settings in delivering care and on the importance of a range of strategies to increase the coverage of evidence-based treatments for priority mental disorders for each demographic stage (childhood, adolescence, adulthood and old age). Our findings clearly indicate three strategies for reducing the treatment gap: increasing the numbers of psychiatrists and other mental health professionals; increasing the involvement of a range of appropriately trained non-specialist providers; and the active involvement of people affected by mental disorders. This is true for both high income and low/middle income countries, though relatively of more importance in the latter. We view this survey as a critically important first step in ascertaining the position of psychiatrists, one of the most influential stakeholder communities in global mental health, in addressing the global challenge of scaling up mental health services to reduce the treatment gap.},
note = {cited By 127},
keywords = {Anxiety Disorder, Article, Atomoxetine, Atypical Antipsychotic Agent, Autism, Benzodiazepine, Bipolar Disorder, Central Nervous System Stimulants, Cholinesterase Inhibitor, Cognitive Therapy, Community Mental Health Center, Conduct Disorder, Cost Effectiveness Analysis, Dementia, Depression, Evidence-based Practice, Family, Family Therapy, Haloperidol, Health Care, Health Care Access, Health Care Delivery, Health Care Personnel, Health Practitioner, Health Survey, Help Seeking Behavior, Home Mental Health Care, Human, Hyperkinesia, Long Term Care, Lowest Income Group, Mental Deficiency, Mental Disease, Mental Health, Mental Health Care, Mental Health Service, Nootropic Agent, Open Ended Questionnaire, Outcome Assessment, Patient Compliance, Personality Disorder, Practice Guideline, Priority Journal, Psychiatry, Psychoeducation, Psychotherapy, Schizophrenia, Serotonin Noradrenalin Reuptake Inhibitor, Serotonin Uptake Inhibitor, Substance Abuse, Therapy, Therapy Delay, Tricyclic Antidepressant Agent, World Health Organization},
pubstate = {published},
tppubtype = {article}
}